Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities

BJU International

Volumn 108, Issue 9, 2011, Pages 1402-1408

  Williams, Naomi ^a   Hughes, Laura J ^b   Turner, Emma L ^c   Donovan, Jenny L ^c   Hamdy, Freddie C ^a   Neal, David E ^b   Martin, Richard M ^c   Metcalfe, Chris ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

primary health care; prostate cancer; PSA testing; screening; socioeconomic differences

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CROSS SECTIONAL STUDY; GENERAL PRACTICE; GENERAL PRACTITIONER; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RETROSPECTIVE STUDY; SOCIAL STATUS; STUDY DESIGN; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENGLAND; FAMILY PRACTICE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80054972161     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10163.x     Document Type: Article

References (29)

1. Sirovich BE, Schwartz LM, Woloshin S,. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 1414-20 (Pubitemid 37430309)
2. Collin SM, Martin RM, Metcalfe C, et al,. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-52
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR,. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9 (Pubitemid 41095147)
4. Andriole GL, Crawford ED, Grubb RL III, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
5. Schröder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
6. Hugosson J, Carlsson S, Aus G, et al,. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
7. Albertsen P,. Lies, damn lies, and cancer statistics. Eur Urol 2009; 56: 592-3
8. Donovan J, Hamdy F, Neal D, et al,. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88
9. Noble S, Donovan J, Turner E, et al,. Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. J Health Serv Res Policy 2009; 14: 77-81
10. Melia J, Moss S, Johns L,. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004; 94: 51-6 (Pubitemid 38980308)
11. Kirkwood BR, Sterne JAC,. Essential Medical Statistics, 2nd edn. Oxford: Blackwell, 2003
12. Pashayan N, Powles J, Brown C, Duffy SW,. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer 2006; 95: 401-5 (Pubitemid 44187607)
13. Mokete M, Shackley DC, Betts CD, O'Flynn KJ, Clarke NW,. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. BJU Int 2006; 97: 266-9
14. Melia J, Coulson P, Moss S, Coleman D,. Effects of a prostate awareness pilot on GP consultations and PSA requests. Fam Pract 2010; 27: 69-76
15. Melia J, Moss S,. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656-7 (Pubitemid 32929459)
16. Roemeling S, Roobol MJ, Otto SJ, et al,. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial. Prostate 2007; 67: 1053-60 (Pubitemid 46983335)
17. Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE,. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 2004; 94: 327-31 (Pubitemid 39120173)
18. Logie J, Clifford GM, Farmer RD,. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 2005; 95: 557-62 (Pubitemid 40311473)
19. Young JM, Muscatello DJ, Ward JE,. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000; 85: 1037-48 (Pubitemid 30348795)
20. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI,. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer 2008; 123: 1924-8
21. Collin SM, Metcalfe C, Donovan J, et al,. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008; 102: 1400-6
22. Roehrborn CG, McConnell JD, Lieber M, et al,. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80 (Pubitemid 29136187)
23. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R,. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985-90 (Pubitemid 38758619)
24. Haidinger G, Madersbacher S, Waldhoer T, Lunglmayr G, Vutuc C,. The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. Eur J Epidemiol 1999; 15: 717-22 (Pubitemid 29493111)
25. Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ,. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer 2009; 101 (Suppl. 2): S92-101
26. Robb K, Stubbings S, Ramirez A, et al. Public awareness of cancer in Britain: a population-based survey of adults. Br J Cancer 2009; 101 (Suppl. 2): S18-23
27. Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP,. Survival from prostate cancer in England and Wales up to 2001. Br J Cancer 2008; 99 (Suppl. 1): S75-7
28. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
29. Lyratzopoulos G, Barbiere JM, Greenberg DC, Wright KA, Neal DE,. Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. BMJ 2010; 340: c1928